ADC’s Label-Expansion Study For Zynlonta Halted For Respiratory Safety

A Phase II study in a frail, older lymphoma population has seen seven respiratory-related deaths along with five other serious adverse events, but so far Zynlonta has been deemed not related to the AEs.